Reuters logo
BRIEF-NW bio announces lifting of clinical hold on DCVax-l phase III trial by FDA
February 6, 2017 / 5:28 PM / 8 months ago

BRIEF-NW bio announces lifting of clinical hold on DCVax-l phase III trial by FDA

Feb 6 (Reuters) - Northwest Biotherapeutics Inc :

* NW Bio announces lifting of clinical hold on DCVax-l phase III trial by FDA; progression-free survival events reached; overall survival events not yet reached

* Trial has accumulated sufficient number of events toward progression-free survival endpoint, but not yet for overall survival endpoint

* Co remains blinded to all trial data, and is only receiving and reporting updates on a blinded basis Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below